---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018005"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-09-01T23:59:59+00:00"
generated_at: "2026-06-23T17:42:37.056689+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics cuts 37% workforce, suspends FIN-211 trial after Takeda deal ends

## Summary
- Reduces workforce by 50 employees (~37% of staff) to cut costs.
- Suspends initiation of Phase 1 trial for FIN-211 (autism candidate).
- Estimates $1.6M in severance and related expenses; charges expected in H2 2022.
- Action follows termination of Takeda IBD collaboration and ongoing strategic review.
- Restructuring substantially complete by Q4 2022; cash runway update to come.

## SEC filing metadata
- accession: 0000950170-22-018005
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022018005/0000950170-22-018005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022018005/fnch-20220901.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018005
- JSON: https://secwatch.observer/filing/0000950170-22-018005.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.